

Annotations for ToxCast and Tox21 High-Throughput Screening Assays: Facilitating Assay Interpretation and Data Use

Background

- Building confidence in new approach methodologies (NAMs) for prioritization and hazard characterization requires accessible and easily interpretable bioactivity data.
- The U.S. Environmental Protection Agency (EPA) Toxicity Forecaster (ToxCast) program makes in vitro medium- and high-throughput screening (HTS) assay data publicly available for thousands of chemicals of interest. The assays included employ a variety of technologies to evaluate the effects of chemical exposure on diverse biological targets.
- To increase accessibility to annotated HTS data, the EPA and National Toxicology Program (NTP) Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM) have annotated over 2,000 assay endpoints from the ToxCast program, including results from the Toxicology Testing in the 21st Century (Tox21) consortium.
- These HTS assay data were annotated using existing controlled bioassay ontologies to facilitate stakeholder understanding, provide terminology that offers additional context, and inform on the biological relevance of the many heterogeneous in vitro HTS assay readouts.

Key Goals for this Project:

- **1.** Identify fields from existing annotations for further reporting needs Leveraging and expanding annotations for HTS data can provide context to facilitate the identification of data gaps, mechanistic plausibility, and further investigation into regulatory-relevant endpoints.
- 2. Map existing annotations to standardized reporting templates Existing assay annotations are mapped to complete standardized data reporting templates, including the internationally recognized OECD guidance document (GD) 211 and OECD Harmonized Template (OHT) 201.
- 3. Ensure all data are publicly accessible and transparent By offering users detailed assay descriptions using the GD 211 format and providing standardized OHT 201 formatted results for each chemical across all tested endpoints, this work renders these complex data streams more approachable and accessible, thereby increasing confidence for the adoption of HTS assay data in next generation chemical assessment.

Approaches to Annotation

Annotating Technological Assay Details

The ToxCast data pipeline, tcpl, is an open-source R package that stores, manages, curve-fits, and visualizes ToxCast data as well as populating the linked MySQL Database, InvitroDB. All ToxCast data is made accessible via the CompTox Chemicals Dashboard (comptox.epa.gov) under the Bioactivity section or download at: https://www.epa.gov/chemical-research/exploring-toxcast-data-downloadable-data. The ToxCast Summary page and well as examples of assay annotation fields describing assay platform and design are displayed below:



Table 1: Example Assay Annotation Fields

Normalized Data Type Organism Burst Assay Tissue Key Positive Control Cell Format Signal Direction Cell Short Name Intended Target Type **Cell Free Component Source** Parameter Readout Type Cell Growth Mode Assay Design Type Assay Footprint **Biological Process Target** Assay Format Type Detection Technology Type Content Readout Type Key Assay Reagent **Dilution Solvent** Technological Target Type **Dilution Solvent Percent Max** Gene Symbol Timepoint Hr


Understanding Biological Interpretation

NICEATM has developed the user-friendly and interactive Integrated Chemical Environment (ICE; ice.ntp.niehs.nih.gov). ICE provides data and computational tools to aid in finding, analyzing, and contextualizing NAMs. In the ICE Search tool, users can find curated HTS (cHTS) data via the Assay Selection feature where assays are grouped by controlled vocabulary terminology to facilitate retrieval of orthologous or complementary assays.

| | Select Assays 👔 | Select Assays 👔 | | | |
|------------------------------|-------------------------------------|----------------------------------|--|--|--|
| egrated mical ironment | CHTS Acute Lethality Sensitization | CHTS Acute Lethality | Sensitization Irritation/Corrosion | | |
| | CHTS | Acute Lethality | Cytotoxicity | | |
| | Abnormal Growth and Differentiation | Dermal | This MOA describes assays relating to cell survival and cell viability. It | | |
| | Angiogenic Process | Inhalation | composed of 117 assays relating to: | | |
| | Cellular Processes | 🔲 🗸 Oral | Cell Survival CUI:C0007620 | | |
| | Cellular Stress Response | In Vivo Acute Oral | Cell Viability Process CUI:C1516362 | | |
| | | In Silico Acute Ora | Cellular Morphology CUI:C1521816 | | |
| | | Mode of Action | Cellular Processes CUI:C1325880 | | |
| | Energy Metabolism Process | Cytotoxicity | | | |
| | Epigenetic Process | DNA Damage | Close | | |
| | Gene Expression | Energy Metabolism Process | | | |
| | Immune and Inflammatory Response | Immune and Inflammatory Response | | | |
| | Neuronal Transmission | | | | |
| | Xenobiotic Metabolism | | 20101 | | |
| | Unannotated | Oxidative Stress | | | |

A.L. Karmaus¹, A. Borrel¹, M. Feshuk², A. Harrill², C. Wittwehr³, N.C. Kleinstreuer⁴

¹Inotiv, RTP, NC; ²EPA/ORD/CCTE, RTP, NC; ³European Commission, JRC, Ispra, Italy; ⁴NIH/NIEHS/DTT/PTB/NICEATM, RTP, NC





OECD Harmonised Templates for Reporting Chemical Test Summaries

Introduction Format and conventions used OECD Harmonised Templates Downloads Updates and history Contact Us


weight of evidence and are underpinned by Adverse Outcome Pathways).

Annotations can be leveraged to populate fields in the OHT 201 form The OHT 201 is a harmonized template for reporting chemical test result summaries for intermediate effects. An example for

"Effect Identification" and "Process" sections is provided below: OECD Template #201: Intermediate effects - mechanistic information (Version [5.2]-[December 2022])

| Line no. | Field name | Field type Display type | Picklist <u>Freetext</u> template | Help text |
|-------------|--------------------------|--|---|---|
| 16. | Effect identification | Header 1 | | Describe the mechanism that can be measu 'Process', 'Object' and 'Action'. As a minim 'Object' and 'Action' must be identified. More (e.g. Cell Activation, CD54 molecule, increase increased). If both Process and Object are the chosen Action (e.g. both process and of et. al (2017) Please refer to the following P/O/A example TG442C, DPRA, kinetic DPRA, and ADRA: |
| 17. | Process | List sup. (<u>picklist</u> with remarks) Display: Basic | Picklist values: - apoptotic process - [GO:0008219] - biosynthetic process - [GO:0009058] - catalytic activity - [GO:0003824] - cell activation - [GO:0001775] - cell death - [GO:0008219] - cell differentiation - [GO:0030154] - cell migration - [GO:0016477] - cell proliferation - [GO:0008283] | Process represents the dynamics of the undbinding) (lves et al, 2017). The Process is a Adverse Outcome Pathway Wiki (https://aojdoi:10.1089/aivt.2017.0017). Select the process that best describes the rifother' to specify the Process and provide a Service (OLS) which is available at https://witerm. If possible please select as Process of Gene Ontology (GO). For most terms there will be several options preferred ontology identifier into the remark. Cytotoxicity data should only be reported as scope of the study to determine cytotoxicity supporting information e.g. for dose selection as a process. Such data are reported as 'O' |

uidance Document for Describing Non-Guideline In Vitro Test Methods 1 / 17 The purpose of this guidance is to harmonise the way non-guideline in vitro methods are described and thereby facilitate an assessment of the relevance of test methods for biological activities and responses of interest, and an assessment of the quality of data produced, irrespective of whether these tests are based on manual protocols or assay protocols adapted for use on automated platforms or high-throughput screening systems (HTS). This guidance outlines the elements considered relevant for providing a comprehensive description of an in vitro method to facilitate the interpretation of results and Assay Endpoint ID: 2 ACEA ER 80hr Assay Title: ACEA 80-hr T47-D Human Breast Cell Proliferation Assay Assay Summary One possible effect of endocrine disrupting chemicals is increased cell growth through perturbation of indocrine pathways linked to cell cycle regulation. Activation of the estrogen receptor (ER) signaling pathway, for example, is one possible mechanism that underlies cell proliferation in hormonally sensitive tissues such as mammary and endometrial tissue. The role of steroid hormones in the regulation of some mammary tumors has been well established (Russo and Russo 2006, Yager and Davidson 2006) and has motivated the development of estrogen pathway-based chemotherapeutics. This assay was designed to identify those chemicals in the ToxCast chemical library with the potential to affect cell growth by activating the estrogen receptor-mediated cell proliferation pathway. These impacts were observed by monitoring changes in electrical impedance on the surface of an electronic cell culture growth plate (Eplates) following 80-hour incubation with test chemicals. Assay Definition Assay Throughput: The assay is conducted on 96-well plates with each plate containing positive controls for proliferation (17β-estradiol) and cytotoxicity (MG132), negative controls (assay media, RPMI 1640), and two concentrations (0.5% and 0.125%) of DMSO solvent controls. Following a 24-hour incubation period, the cells are exposed to test chemicals for 80 hours and response is monitored no less than once per hour. Experimental System: T-47D human breast carcinoma ductal cell line, originally derived in 1974 from pleural effusion of a 57year-old patient, which exhibits epithelial-like morphology (Horwitz et al. 1978, Keydar et al. 1979). Xenobiotic Biotransformation Potential: T-47D cells contain specific high affinity receptors for estradiol, progesterone, glucocorticoid and androgen (Horwitz et al. 1978). Some potential for P450 mediated metabolism is present, e.g. CYP1A1, CYP1A2, CYP1B1 (Angus et al. 1999, Hevir et al. 2011, MacPherson and Matthews 2010, Spink et al. 2002, Spink et al. 1998), CYP2B6 (Lo et al. 2010), CYP3A4 (Nagaoka et al. 2006) and CYP2C8 (Mitra et al. 2011), as well as some experimental evidence for the capacity to retain expression of some phase II metabolizing enzymes, e.g., UGTs (Harrington et al. 2006, Hevir et al. 2011), GSTs (Hevir et al. 2011) and sulphotransferases (e.g., SULT1A3(Miki et al. 2006), SULT1E1, SULT2B1 (Hevir et al. 2011)) Basic Procedure



ther observations




Table 2: OHT 201 "Effect Identification" source annotations Invitrodb: Assay Component Endpoint Name Invitrodb: Intended Target Invitrodb:Technological Target Type Invitrodb: Gene Symbol Invitrodb: Signal Direction

 Table 3: OHT 201 "Process" source

 annotations

Invitrodb: Assay Design Type Invitrodb: Biological Process Target ICE: Mode of Action ICE: Mechanistic Target

Accessing These Data





Summary

Increased accessibility to annotated HTS data provides context that facilitates the identification of data gaps, mechanistic plausibility, and further investigation into regulatory-relevant endpoints

- OHT 201 and GD 211.

- intermediate effects.
- ICE web tools.

Acknowledgements

Subscribe to NICEATM News email list https://ntp.niehs.nih.gov/go/niceatm

This project was funded with federal funds from NIEHS, NIH under Contract No. HHSN273201500010C. This abstract does not reflect official EPA policy.

Please feel free to contact: Agnes Karmaus (agnes.karmaus@inotivco.com)

• Tox21 and ToxCast annotations were retrieved from invitroDB and ICE's cHTS data.

• Assay annotations are leveraged to work toward completing standardized data reporting templates

• GD 211 serves as a standard for comprehensive assay documentation describing non-guideline in vitro test methods and their interpretation.

• The OHT 201 is a harmonized template for reporting chemical test result summaries for

• Resulting standardized forms will be available from IUCLID, CompTox Chemicals Dashboard, and

This project was a collaboration between NICEATM, EPA, and the JRC

